NCT02243358View on ClinicalTrials.gov

Phase II Study of Chemo-Radiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

June 28, 2017

Study Completion Date

January 14, 2020

Conditions
Pancreas Neoplasm Malignant Resectable
Interventions
DRUG

Folfox6

DRUG

Gemcitabine

RADIATION

Radiation Therapy

PROCEDURE

Pancreaticoduodenectomy with retroperitoneal lymphadenectomy

Trial Locations (1)

48202

Henry Ford Health System, Detroit

All Listed Sponsors
lead

Henry Ford Health System

OTHER

NCT02243358 - Phase II Study of Chemo-Radiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer | Biotech Hunter | Biotech Hunter